ClinicalTrials.gg
CompletedNCT00666536EXTRAUpdated Oct 27, 2016Results posted

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

A Phase 4 interventional study of valsartan and amlodipine and valsartan and amlodipine in Hypertension, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
728
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
28th of 139
728 · median 198
Started
2008
with 6 others
Phase 4
67 of 140
none open now
Registered
91st of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 28th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2008, is one of 67 in phase 4, and was the 91st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • adults
  • Valsartan + Amlodipine
  • Angiotensin Receptor Blockers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients
  • 18 Years of age or older
  • Mean Sitting Systolic Blood Pressure (the top number) greater than or equal to 150 mmHg and lower than 200 mmHg while on Angiotensin-Receptor Blocker monotherapy for a minimum period of 28 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Mean Sitting Systolic Blood Pressure (the top number) greater than or equal to 200 mmHg and/or Mean Sitting Diastolic Blood Pressure greater than or equal to 120 mmHg
  • (mini-stroke), myocardial infarction (heart attack), all types of revascularization procedures in the last 6 months
  • Treatment with valsartan or any combination antihypertensive treatment with 28 days prior to screening (Visit 1)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
728 participants (actual)

Study arms

  • Active comparator
    Aggressive treatment regimen (5/320 mg to 10/320 mg)

    Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)

    Drug: valsartan and amlodipine

  • Active comparator
    Moderate treatment regimen (5/160 mg)

    Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)

    Drug: valsartan and amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12

    Time frame: Weeks 2, 4, 8 and 12

  2. Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)

    Time frame: Baseline and Week 4

  3. Change From Baseline to Weeks 2, 8 and 12 in MSSBP

    Time frame: Baseline and Weeks 2, 8 and 12

  4. Change From Baseline to Weeks 2, 8 and 12 in MSDBP

    Time frame: Baseline and Weeks 2, 8 and 12

  5. Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12

    Time frame: Weeks 2, 4, 8 and 12

07

Results

Posted Dec 10, 2010

Participant flow

Participant flow — Overall Study
MilestoneAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Started369359
Completed336322
Not completed3337
Withdrew: Adverse event919
Withdrew: Unsatisfactory therapeutic effect20
Withdrew: Protocol deviation(s)86
Withdrew: Withdrawal by subject109
Withdrew: Lost to follow-up43

Outcome measures

PrimaryChange From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)
Time frame:
Baseline and Week 4
Reported as:
Mean · mmHg
Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)
mmHgAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Baseline MSSBP163.9 ± 11.85163.3 ± 11.40
Week 4 MSSBP140.9 ± 14.61144.4 ± 14.21
Change From Baseline to Week 4 in MSSBP-23.0 ± 14.60-18.9 ± 13.92
SecondaryPercentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12
Time frame:
Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of Patients
Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12
Percentage of PatientsAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Week 225.125.8
Week 443.731.1
Week 861.746.2
Week 1259.850.7
SecondaryChange From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)
Time frame:
Baseline and Week 4
Reported as:
Mean · mmHg
Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)
mmHgAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Baseline MSDBP95.5 ± 11.1995.0 ± 10.33
Week 4 MSDBP84.8 ± 11.4786.2 ± 9.6
Change From Baseline to Week 4 in MSDBP-10.7 ± 9.39-8.8 ± 9.08
SecondaryChange From Baseline to Weeks 2, 8 and 12 in MSSBP
Time frame:
Baseline and Weeks 2, 8 and 12
Reported as:
Mean · mmHg
Change From Baseline to Weeks 2, 8 and 12 in MSSBP
mmHgAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Baseline MSSBP163.9 ± 11.85163.3 ± 11.40
Week 2 MSSBP147.0 ± 14.93146.0 ± 14.80
Change From Baseline to Week 2 in MSSBP-16.9 ± 13.94-17.3 ± 13.80
Week 8 MSSBP136.0 ± 15.27140.5 ± 15.91
Change From Baseline to Week 8 in MSSBP-27.9 ± 16.08-22.8 ± 16.15
Week 12 MSSBP135.7 ± 14.97139.2 ± 15.63
Change From Baseline to Week 12 in MSSBP-28.1 ± 16.59-24.1 ± 16.07
SecondaryChange From Baseline to Weeks 2, 8 and 12 in MSDBP
Time frame:
Baseline and Weeks 2, 8 and 12
Reported as:
Mean · mmHg
Change From Baseline to Weeks 2, 8 and 12 in MSDBP
mmHgAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Baseline MSDBP95.5 ± 11.1995.0 ± 10.33
Week 2 MSDBP88.2 ± 10.9387.1 ± 10.38
Change From Baseline to Week 2 in MSDBP-7.3 ± 8.51-7.9 ± 9.66
Week 8 MSDBP81.6 ± 11.1584.0 ± 11.39
Change From Baseline to Week 8 in MSDBP-13.9 ± 9.97-11.0 ± 10.33
Week 12 MSDBP81.5 ± 10.6283.8 ± 10.61
Change From Baseline to Week 12 in MSDBP-14.0 ± 10.41-11.2 ± 10.48
SecondaryPercentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12
Time frame:
Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of Patients
Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12
Percentage of PatientsAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Week 231.132.5
Week 449.237.5
Week 866.149.6
Week 1262.855.7

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aggressive Treatment Regimen (5/320 mg to 10/320 mg)—4/369 (1.1%)50/369 (13.6%)
Moderate Treatment Regimen (5/160 mg)—10/359 (2.8%)29/359 (8.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Angina pectorisCardiac disorders0/3692/359
Myocardial infarctionCardiac disorders0/3692/359
Abdominal painGastrointestinal disorders0/3692/359
Cardiac arrestCardiac disorders0/3691/359
Cardiac failure congestiveCardiac disorders0/3691/359
PalpitationsCardiac disorders0/3691/359
TachycardiaCardiac disorders0/3691/359
Small intestinal obstructionGastrointestinal disorders0/3691/359
Gait disturbanceGeneral disorders0/3691/359
Non-cardiac chest painGeneral disorders0/3691/359
Most frequent other events
Most frequent other events
EventAggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)
Oedema peripheralGeneral disorders32/36916/359
DizzinessNervous system disorders19/36914/359

Baseline characteristics

Age, Customized
Age, Customized(participants)Aggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)Total
< 65 years302292594
>=65 years6465129
Age, Continuous
Age, Continuous(years)Aggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)Total
Mean54.4 ± 10.9855.0 ± 10.9854.7 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)Aggressive Treatment Regimen (5/320 mg to 10/320 mg)Moderate Treatment Regimen (5/160 mg)Total
Female157157314
Male209200409
08

Study locations

1 site
  • Egan Healthcare
    Metairie, Louisiana 70002, United States
09

References and documents

Publications

  • Oparil S, Giles T, Ofili EO, Pitt B, Seifu Y, Hilkert R, Samuel R, Sowers JR. Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens. 2011 Jan;29(1):161-70. doi: 10.1097/HJH.0b013e32834000a7. PubMed 21045734 ↗
  • Giles TD, Oparil S, Ofili EO, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers JR. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Blood Press Monit. 2011 Apr;16(2):87-95. doi: 10.1097/MBP.0b013e328344c713. PubMed 21386706 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008 and a primary completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 25, 2008
Start
Mar 2008
Primary completionActual
Jan 2009
Results first posted
Dec 10, 2010
Last update
Oct 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00666536
Lead sponsor
Novartis
First posted
Apr 25, 2008
Start date
Mar 2008
Primary completion
Jan 2009
Results posted
Dec 10, 2010
Last update
Oct 27, 2016

Study contacts

Suzanne Oparil, MD et al
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion